Abstract
No specific drugs have been found for the COVID-19 pandemic until now. The drug administration follows the national standards imposed to prevent the worsening of the patient's condition in the hope of recovery. The purpose of this study was to look at the effect of drug administration on hematologic parameters before and after the administration of drugs. This research method is cohort-based observational with the collection of retrospective medical record data from March to October 2020 at the Central Jakarta Private Hospital, Indonesia. The results showed improvement values in hematologic parameter values in eosinophils, neutrophils, monocytes, and neutrophil-lymphocyte ratios, and statistically, the parameter of eosinophils values is a significant difference after administering the drug.
Highlights
COVID-19 or Coronavirus disease is a disease caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(Common, 2003)
In mid-December was reported the first case of COVID-19 (Pormohammad et al, 2020), Where there are five patients with symptoms of fever, cough, and tightness accompanied by acute respiratory conditions, one in five of these patients died (Liu et al, 2020)
The inclusion criteria comprised of patients over 12 years old with a confirmed COVID-19 diagnosis, with or without comorbidities, drug therapy, and clinical laboratory examinations
Summary
COVID-19 or Coronavirus disease is a disease caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(Common-, 2003). This new disease and has spread rapidly from Wuhan (Hubei province) to other provinces in China and around the world including Jakarta, Indonesia New variants and the roll-out of vaccinations have altered the symptomatology experienced by patients(Thomson et al, 2021) Another way to prevention, the Indonesian government provides continued education on COVID-19 prevention with the 5M health protocol and the importance of multivitamins in the COVID-19 pandemic to increase immunity and reduce transmission rates(Aulia et al, 2021)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have